# US 2024/0254539 A1 · Detection of variant esr1 sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254539 A1
- Document ID: US20240254539A1
- Status: Published application
- Kind: A1
- Application number: 18/240,453
- Filed: 2023-08-31
- Published: 2024-08-01
- Earliest claimed: 2022-08-31
- Assignees: Saga Diagnostics AB
- Applicants: Saga Diagnostics AB
- Inventors: Miguel Alcaide; Anthony Miles George; Lao Hayamizu Saal
- Web page: https://patentgrep.com/patent/US20240254539A1

## CPC

- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method for detecting variant nucleic acid sequences in ESR1, which are often found in low-abundance, using dPCR and patterns in multi-dimensional plots indicative of a particular variant sequence.

## Claims

### Claim 1

A method for detecting a plurality of recurrent variant estrogen receptor 1 (ESR1) nucleic acid sequences, the method comprising:
obtaining a sample comprising a ESR1 nucleic acids from a subject;
partitioning the sample into reaction partitions;
performing a digital polymerase chain reaction (dPCR) in each partition using:
a probe that comprises a first optical label and specifically binds to amplicons containing a wildtype ESR1 sequence;
a first set of different probes, wherein each probe comprises a second optical label, wherein each different probe of the set specifically binds to amplicons that comprise a different, variant sequence, wherein said different variant sequences comprise at least a first ESR1 variant sequence, a second ESR1 variant sequence, and a third ESR1 variant sequence;
generating a two-color plot from the detected optical signals using a dedicated channel for each optical label; and
identifying the presence of one or more ESR1 variant sequences based on a deviation from an expected wild-type cluster on the two-color plot.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dPCR step further uses a probe that comprises a third optical label, wherein the probe is specific for a fourth ESR1 variant sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the dPCR step further uses a probe that comprises a third optical label, wherein the probe is specific for the first ESR1 variant sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein the generating step comprises generating a two-color plot using the dedicated channel for the second optical label versus the dedicated channel for the third optical label, wherein the presence of the first ESR1 sequence is based on a shift in the deviation from a two-color plot of the first and second optical channels and the two-color plot of the second and third optical channels.

### Claim 5 (depends on 4)

The method of claim 4, wherein the amplicons are further contacted with an unlabeled probe that specifically binds to a wildtype sequence at the genomic location of the first ESR1 variant sequence.

### Claim 6 (depends on 4)

The method of claim 4, wherein the dPCR step further uses: a second set of different probes, wherein each probe comprises a fourth optical label, wherein each different probe of the set specifically binds to amplicons that comprise a different, variant sequence, wherein said different variant sequences comprise a fifth ESR1 variant sequence, a sixth ESR1 variant sequence, and a seventh ESR1 variant sequence.

### Claim 7 (depends on 6)

The method of claim 6, wherein the dPCR step further uses: a third set of different probes, wherein each probe comprises a fifth optical label, wherein each different probe of the set specifically binds to amplicons that comprise a different, variant sequence, wherein said different variant sequences comprise an eighth ESR1 variant sequence, a ninth ESR1 variant sequence, and a tenth ESR1 variant sequence.

### Claim 8 (depends on 7)

The method of claim 7, wherein prior to the dPCR step, the method includes an amplifying step that specifically amplifies two different ESR1 sequences, thereby producing a first amplicon and a second amplicon.

### Claim 9 (depends on 8)

The method of claim 8, wherein the first and second amplicons are less than 65 bp in length.

### Claim 10 (depends on 9)

The method of claim 9, wherein the first amplicon includes genomic locations of the second, third, fourth, fifth, sixth, seventh, eighth, ninth, and tenth ESR1 variant sequences and the second amplicon includes a genomic location of the first variant ESR1 sequence.

### Claim 11 (depends on 10)

The method of claim 10, wherein the first amplicon includes an ESR1 sequence encoding amino acids 526 through 538 of SEQ ID NO: 2.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second amplicon includes an ESR1 sequence encoding amino acid 380 of SEQ ID NO: 2.

### Claim 13 (depends on 12)

The method of claim 12, wherein a mutant allele frequency for each ESR1 variant sequence is known.

### Claim 14 (depends on 7)

The method of claim 7, wherein the optical labels comprise FAM, HEX, CY5, ROX, and ATTO550.

### Claim 15 (depends on 1)

The method of claim 1, wherein the sample comprises highly fragmented target nucleic acids.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sample comprises cell-free DNA (cfDNA).

### Claim 17 (depends on 15)

The method of claim 15, wherein the sample is selected from the group consisting of: a tissue sample, a circulating tumor cell, a tissue biopsy sample, a formalin-fixed, paraffin-embedded (FFPE) tissue sample, and a liquid biopsy sample.

### Claim 20 (depends on 7)

The method of claim 7, wherein: the first variant sequence comprises the sequence of SEQ ID NO: 3; the second variant sequence comprises the sequence of SEQ ID NO: 4; the third variant sequence comprises the sequence of SEQ ID NO: 5; the fourth variant sequence comprises the sequence of SEQ ID NO: 6; the fifth variant sequence comprises the sequence of SEQ ID NO: 7; the sixth variant sequence comprises the sequence of SEQ ID NO: 8; the seventh variant sequence comprises the sequence of SEQ ID NO: 9; the eighth variant sequence comprises the sequence of SEQ ID NO: 10; the ninth variant sequence comprises the sequence of SEQ ID NO: 11; and/or the tenth variant sequence comprises the sequence of SEQ ID NO: 12.
